Research ArticleTheranostics
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W. Sauter, Rosalba Mansi, Ulrich Hassiepen, Lionel Muller, Tania Panigada, Stefan Wiehr, Anna-Maria Wild, Susanne Geistlich, Martin Béhé, Christof Rottenburger, Damian Wild and Melpomeni Fani
Journal of Nuclear Medicine March 2019, 60 (3) 393-399; DOI: https://doi.org/10.2967/jnumed.118.207845
Alexander W. Sauter
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany
Rosalba Mansi
3Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
Ulrich Hassiepen
4Novartis Pharma AG, Institutes for Biomedical Research, Novartis Campus, Basel, Switzerland; and
Lionel Muller
4Novartis Pharma AG, Institutes for Biomedical Research, Novartis Campus, Basel, Switzerland; and
Tania Panigada
4Novartis Pharma AG, Institutes for Biomedical Research, Novartis Campus, Basel, Switzerland; and
Stefan Wiehr
2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany
Anna-Maria Wild
2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany
Susanne Geistlich
5Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland
Martin Béhé
5Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland
Christof Rottenburger
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Damian Wild
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Melpomeni Fani
3Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 3
March 1, 2019
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W. Sauter, Rosalba Mansi, Ulrich Hassiepen, Lionel Muller, Tania Panigada, Stefan Wiehr, Anna-Maria Wild, Susanne Geistlich, Martin Béhé, Christof Rottenburger, Damian Wild, Melpomeni Fani
Journal of Nuclear Medicine Mar 2019, 60 (3) 393-399; DOI: 10.2967/jnumed.118.207845
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Alexander W. Sauter, Rosalba Mansi, Ulrich Hassiepen, Lionel Muller, Tania Panigada, Stefan Wiehr, Anna-Maria Wild, Susanne Geistlich, Martin Béhé, Christof Rottenburger, Damian Wild, Melpomeni Fani
Journal of Nuclear Medicine Mar 2019, 60 (3) 393-399; DOI: 10.2967/jnumed.118.207845